Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5310 DNA Vaccine for COVID-19 in Healthy Adults
NCT04673149Phase 2Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GLS-5310 in coronavirus disease 2019 (COVID-19), sponsored by GeneOne Life Science, Inc.. Started Dec 2020; status: completed.
02
Drugs
GLS-5310
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04673149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673149.